- Home
- FBIOP vs DMII Comparison
FBIOP vs DMII Comparison
Compare FBIOP & DMII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$11.77
Company Overview
Basic Information| Metric | FBIOP | DMII |
|---|---|---|
| Founded | N/A | 2024 |
| Country | United States | United States |
| Employees | 101 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | FBIOP | DMII |
|---|---|---|
| Price | $11.77 | $10.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 33.6K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $9.94 |
| 52 Week High | N/A | $10.80 |
Technical Indicators
Market Signals| Indicator | FBIOP | DMII |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 80.86 |
| Support Level | $11.85 | $9.95 |
| Resistance Level | $12.90 | $9.97 |
| Average True Range (ATR) | 0.54 | 0.02 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 31.71 | 100.00 |
Price Performance
Historical Comparison FBIOP
DMII
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.